Wells Fargo & Company Reaffirms “Market Perform” Rating for Illumina, Inc. (ILMN)
Illumina, Inc. (NASDAQ:ILMN)‘s stock had its “market perform” rating restated by equities research analysts at Wells Fargo & Company in a report issued on Wednesday, The Fly reports. They presently have a $205.00 price target on the life sciences company’s stock, up from their previous price target of $200.00. Wells Fargo & Company’s price objective suggests a potential downside of 2.76% from the stock’s current price.
A number of other research analysts have also recently weighed in on ILMN. Vetr raised shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 price objective for the company in a research note on Tuesday, June 27th. Barclays PLC reissued a “hold” rating and set a $150.00 price objective on shares of Illumina in a research note on Wednesday, July 19th. Canaccord Genuity reissued a “buy” rating and set a $230.00 price objective (up from $215.00) on shares of Illumina in a research note on Thursday, October 12th. BidaskClub cut shares of Illumina from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 25th. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $226.00 price objective (up from $202.00) on shares of Illumina in a research note on Monday, October 9th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $194.23.
Illumina (NASDAQ:ILMN) opened at 210.82 on Wednesday. Illumina has a one year low of $119.37 and a one year high of $214.50. The stock’s 50 day moving average price is $206.01 and its 200 day moving average price is $187.81. The firm has a market capitalization of $30.78 billion, a PE ratio of 42.30 and a beta of 0.76.
Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The company had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. During the same period last year, the company posted $0.97 earnings per share. The firm’s quarterly revenue was up 17.6% compared to the same quarter last year. Analysts expect that Illumina will post $3.65 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/25/wells-fargo-company-reaffirms-market-perform-rating-for-illumina-inc-ilmn.html.
In other Illumina news, SVP Mostafa Ronaghi sold 10,000 shares of Illumina stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $195.00, for a total value of $1,950,000.00. Following the transaction, the senior vice president now owns 76,585 shares in the company, valued at approximately $14,934,075. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jay T. Flatley sold 22,540 shares of Illumina stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $195.21, for a total transaction of $4,400,033.40. Following the completion of the transaction, the director now owns 539,176 shares in the company, valued at approximately $105,252,546.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 182,766 shares of company stock worth $36,411,334. 1.60% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of ILMN. Teachers Advisors LLC lifted its holdings in shares of Illumina by 60.7% during the 1st quarter. Teachers Advisors LLC now owns 384,300 shares of the life sciences company’s stock valued at $65,577,000 after acquiring an additional 145,231 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Illumina by 3.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 264,925 shares of the life sciences company’s stock valued at $45,211,000 after acquiring an additional 9,017 shares in the last quarter. KCG Holdings Inc. acquired a new position in shares of Illumina during the 1st quarter valued at $290,000. AQR Capital Management LLC lifted its holdings in shares of Illumina by 58.9% during the 1st quarter. AQR Capital Management LLC now owns 109,234 shares of the life sciences company’s stock valued at $18,640,000 after acquiring an additional 40,477 shares in the last quarter. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Illumina during the 1st quarter valued at $289,000. Institutional investors and hedge funds own 93.34% of the company’s stock.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.